Sign In
Buy OCUL
$8.35
+0.0400 (+0.481%)
At Close: Jun 03, 2026
BEDFORD, Mass., April 14, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative ther
What Makes Ocular Therapeutix (OCUL) a Good Fit for 'Trend Investing'
10:32am, Wednesday, 08'th Mar 2023
Ocular Therapeutix (OCUL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed thr
Ocular Therapeutix, Inc. (OCUL) Q4 2022 Earnings Call Transcript
11:07pm, Monday, 06'th Mar 2023
Ocular Therapeutix, Inc. (NASDAQ:OCUL ) Q4 2022 Earnings Conference Call March 6, 2023 4:30 PM ET Company Participants Donald Notman - Chief Financial Officer Antony Mattessich - President & Chief Exe
Ocular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue Estimates
06:49pm, Monday, 06'th Mar 2023
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 4% and 3.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Ocular Therapeutix: A Promising Turnaround Play
03:00pm, Friday, 03'rd Mar 2023
As a turnaround equity, Ocular Therapeutix, Inc. is showing signs of a successful comeback. OTX-TKI Phase 1 data for wet-AMD is quite robust.
Why Shares of Ocular Therapeutix Jumped This Week
05:15pm, Thursday, 16'th Feb 2023
A promising report of a therapy in a phase 1 trial gave the stock a lift.
Next Round Of Financing Will Be Transformational For Ocular Therapeutix
09:01am, Tuesday, 14'th Feb 2023
Ocular Therapeutix is a promising platform play poised to disruptively transform ophthalmology. Based on its innovative and validated hydrogel platform, Ocular can fill and expand its pipeline with un
Ocular Therapeutix (OCUL) Moves 35.1% Higher: Will This Strength Last?
05:16am, Tuesday, 14'th Feb 2023
Ocular Therapeutix (OCUL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price i
Ocular Therapeutix: A 'Buy' On Maturing Wet AMD Data
09:09pm, Sunday, 12'th Feb 2023
This weekend, OCUL released very encouraging data in wet AMD. I review this data herein, noting, in particular, the reduction in treatment burden associated with OCUL's product relative to the current
Ocular Therapeutix™ to Participate at Three Upcoming Investor Conferences
08:00am, Tuesday, 08'th Nov 2022
BEDFORD, Mass.
Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates (Revised)
06:46am, Tuesday, 08'th Nov 2022
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -30.43% and 18.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock
Ocular Therapeutix, Inc. (OCUL) Q3 2022 Earnings Call Transcript
08:45pm, Monday, 07'th Nov 2022
Ocular Therapeutix, Inc. (NASDAQ:OCUL ) Q3 2022 Earnings Conference Call November 7, 2022 4:30 PM ET Company Participants Donald Notman – Chief Financial Officer Antony Mattessich – President and
Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates
06:56pm, Monday, 07'th Nov 2022
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -34.78% and 18.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock
Ocular Therapeutix™ To Report Third Quarter 2022 Financial Results
06:00am, Monday, 24'th Oct 2022
BEDFORD, Mass.
Ocular Therapeutix (OCUL) Soars 24.2%: Is Further Upside Left in the Stock?
10:32am, Friday, 30'th Sep 2022
Ocular Therapeutix (OCUL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the nea
